Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,401 signal articles · 111 in last 24h · 116,052 total before filter · latest 42m ago
111last 24h
1718last 7d
285● bullish (7d)
155● bearish (7d)
205publishers
AllMacro315Earnings795M&A98Regulatory26Product16Analyst24
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
SpaceX shares plummet after earnings as analysts back long-term outlook
Proactive11d agoneutral
SpaceX shares plummet after earnings as analysts back long-term outlook

SpaceX Corp (NASDAQ:SPCX) shares remained under pressure on Wednesday, with shares falling about 13% to around $109, as analysts remained broadly positive following the company's first earnings report as a public company, arguing the results reinforced its long-term growth outlook despite...

One Stop Systems Q2 Earnings Call Highlights
MarketBeat11d agoneutral
One Stop Systems Q2 Earnings Call Highlights

One Stop Systems (NASDAQ:OSS) reported second-quarter 2026 revenue growth of 62.3% from continuing operations and raised its full-year revenue growth outlook, citing record bookings, expanding customer relationships and increased demand for ruggedized artificial intelligence and high-performance com

SpaceX shares tumble despite earnings beat
CoinDesk11d agoneutralVIDEO
SpaceX shares tumble despite earnings beat

SpaceX reported its first quarterly results as a public company, beating on revenue but falling 11% as investors focused on heavy capital spending. Its 18,712 bitcoin lost roughly $195 million in value during the quarter. CoinDesk's Jennifer Sanasie hosts "CoinDesk Daily."

Popular crypto stock sinks after disappointing Q2 earnings
TheStreet11d agoneutral
Popular crypto stock sinks after disappointing Q2 earnings

Galaxy Digital (GLXY) shares fell more than 11% on Aug. 5 after the crypto financial services firm reported a second-quarter net loss of $85 million, weighed down by falling digital asset prices despite continued expansion of its artificial intelligence infrastructure business. The company posted ...

Kymera Therapeutics Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027. Chief Executive Officer